US Bancorp DE trimmed its holdings in Pfizer Inc. (NYSE:PFE - Free Report) by 9.4% in the 2nd quarter, according to the company in its most recent filing with the Securities and Exchange Commission (SEC). The institutional investor owned 4,721,304 shares of the biopharmaceutical company's stock after selling 491,946 shares during the quarter. US Bancorp DE owned about 0.08% of Pfizer worth $114,445,000 as of its most recent filing with the Securities and Exchange Commission (SEC).
Several other institutional investors also recently modified their holdings of the business. Bessemer Group Inc. grew its position in Pfizer by 11.1% during the 1st quarter. Bessemer Group Inc. now owns 132,478 shares of the biopharmaceutical company's stock valued at $3,358,000 after purchasing an additional 13,228 shares during the last quarter. Capital Advisors Inc. OK grew its position in Pfizer by 1.2% during the 1st quarter. Capital Advisors Inc. OK now owns 1,413,472 shares of the biopharmaceutical company's stock valued at $35,817,000 after purchasing an additional 17,032 shares during the last quarter. CHURCHILL MANAGEMENT Corp purchased a new stake in Pfizer during the 1st quarter valued at about $8,283,000. Westbourne Investments Inc. purchased a new stake in Pfizer during the 1st quarter valued at about $2,411,000. Finally, Bourne Lent Asset Management Inc. grew its position in Pfizer by 90.8% during the 2nd quarter. Bourne Lent Asset Management Inc. now owns 38,255 shares of the biopharmaceutical company's stock valued at $927,000 after purchasing an additional 18,200 shares during the last quarter. 68.36% of the stock is currently owned by institutional investors.
Pfizer Stock Performance
PFE opened at $25.67 on Thursday. The company has a current ratio of 1.16, a quick ratio of 0.85 and a debt-to-equity ratio of 0.65. The company has a market cap of $145.95 billion, a price-to-earnings ratio of 13.65, a PEG ratio of 0.86 and a beta of 0.55. The company's 50 day moving average is $24.79 and its 200 day moving average is $24.15. Pfizer Inc. has a 12-month low of $20.92 and a 12-month high of $30.43.
Pfizer (NYSE:PFE - Get Free Report) last posted its quarterly earnings data on Tuesday, August 5th. The biopharmaceutical company reported $0.78 earnings per share (EPS) for the quarter, topping analysts' consensus estimates of $0.58 by $0.20. The company had revenue of $14.65 billion for the quarter, compared to the consensus estimate of $13.43 billion. Pfizer had a net margin of 16.84% and a return on equity of 21.42%. The firm's revenue was up 10.3% compared to the same quarter last year. During the same quarter last year, the firm posted $0.60 earnings per share. Pfizer has set its FY 2025 guidance at 2.900-3.100 EPS. On average, equities research analysts predict that Pfizer Inc. will post 2.95 EPS for the current year.
Analysts Set New Price Targets
PFE has been the topic of several recent analyst reports. Morgan Stanley increased their price objective on shares of Pfizer from $32.00 to $33.00 and gave the company an "equal weight" rating in a research report on Wednesday, August 6th. Weiss Ratings reissued a "hold (c-)" rating on shares of Pfizer in a research report on Wednesday. Citigroup raised their price target on shares of Pfizer from $25.00 to $26.00 and gave the company a "neutral" rating in a report on Wednesday, August 6th. Bank of America raised their price target on shares of Pfizer from $28.00 to $30.00 and gave the company a "neutral" rating in a report on Friday, October 3rd. Finally, UBS Group reaffirmed a "neutral" rating and set a $28.00 price target on shares of Pfizer in a report on Wednesday, October 1st. Two analysts have rated the stock with a Strong Buy rating, four have assigned a Buy rating, twelve have assigned a Hold rating and one has given a Sell rating to the company. According to data from MarketBeat, the stock presently has a consensus rating of "Hold" and an average target price of $28.41.
Check Out Our Latest Report on PFE
Pfizer Company Profile
(
Free Report)
Pfizer Inc discovers, develops, manufactures, markets, distributes, and sells biopharmaceutical products in the United States, Europe, and internationally. The company offers medicines and vaccines in various therapeutic areas, including cardiovascular metabolic, migraine, and women's health under the Eliquis, Nurtec ODT/Vydura, Zavzpret, and the Premarin family brands; infectious diseases with unmet medical needs under the Prevnar family, Abrysvo, Nimenrix, FSME/IMMUN-TicoVac, and Trumenba brands; and COVID-19 prevention and treatment, and potential future mRNA and antiviral products under the Comirnaty and Paxlovid brands.
Further Reading
Want to see what other hedge funds are holding PFE? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Pfizer Inc. (NYSE:PFE - Free Report).
This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest and most accurate reporting. This story was reviewed by MarketBeat's editorial team prior to publication. Please send any questions or comments about this story to contact@marketbeat.com.
Before you consider Pfizer, you'll want to hear this.
MarketBeat keeps track of Wall Street's top-rated and best performing research analysts and the stocks they recommend to their clients on a daily basis. MarketBeat has identified the five stocks that top analysts are quietly whispering to their clients to buy now before the broader market catches on... and Pfizer wasn't on the list.
While Pfizer currently has a Hold rating among analysts, top-rated analysts believe these five stocks are better buys.
View The Five Stocks Here
Just getting into the stock market? These 10 simple stocks can help beginning investors build long-term wealth without knowing options, technicals, or other advanced strategies.
Get This Free Report
Like this article? Share it with a colleague.
Link copied to clipboard.
